FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

October Deadline for New Adverse Event Reporting Standard

[ Price : $8.95]

FDA says beginning 10/1 it will require drugmakers and other regulated entities to adopt updated international data standards for ...

Context Therapeutics Ovarian Cancer Drug Wins Fast Track

[ Price : $8.95]

FDA grants Context Therapeutics a fast-track designation for its experimental therapy CTIM-76 for treating platinum-resistant ovar...

HHS Weighs Reversal of FDA Peptide Restrictions Despite Safety Concerns

[ Price : $8.95]

HHS is considering reversing a 2023 FDA decision that deemed a group of peptide drugs too risky for use by compounding pharmacies,...

CBER File Over Protest SOPP

[ Price : $8.95]

CBER publishes a Standard Operating Policy and Procedure on filing an application over protest after a Center refusal-to-file deci...

FDA Expanding Real-World Evidence Use in Device Regulation

[ Price : $8.95]

CDRH leaders describe efforts to expand the use of real-world evidence in a range of medical device regulatory activities.

FDA Enforcement Discretion for Some Hemp CBD Products

[ Price : $8.95]

FDA says it will exercise enforcement discretion and not enforce specific sections of the Federal Food, Drug, and Cosmetic Act as ...

Trump Plans New Tariffs on Pharmaceutical Industry

[ Price : $8.95]

President Trump prepares to impose sweeping new tariffs on certain pharmaceutical imports, targeting companies that have not agree...

FDA Denies CAD/CADt Device 510(k) Exemption Petition

[ Price : $8.95]

FDA denies a petition seeking a partial exemption of 510(k) requirements for some specific radiology computer-aided detection and/...

Bipartisan Senators Urge FDA to Pre-Screen Certain Drug Ads

[ Price : $8.95]

Two bipartisan senators press FDA to take a more proactive role in policing prescription drug advertising, citing a surge in misle...

FDA Accepts Ultragenyx Resubmission for Gene Therapy

[ Price : $8.95]

Ultragenyx Pharmaceutical refiles a BLA seeking accelerated approval for UX111, an AAV9 gene therapy for the treatment of Sanfilip...